Ozempic face and loose skin: what dermatologists actually know

What did @drrazankadry actually say?

Honestly? Very little that's usable. The transcript captured from this video is largely unintelligible, producing fragments like "There is a house in use" and "It all rises in love" rather than coherent medical claims. Whatever @drrazankadry intended to communicate about GLP-1 medications, loose skin, or "Ozempic face" did not make it into any readable transcript.

The hashtags tell us the intended topic: loose skin following GLP-1-driven weight loss, a subject the creator, identified as a dermatologist based in Dubai, appears to address regularly. But we cannot fact-check words that were not recorded accurately. What we can do is fact-check the topic itself, because the hashtags signal exactly what conversation this video is participating in.

Does the science back up concerns about Ozempic face and loose skin?

Yes, substantially. Rapid weight loss from any cause, including GLP-1 receptor agonists like semaglutide and tirzepatide, is well-documented to reduce facial fat volume and skin elasticity. The term "Ozempic face" is colloquial, not clinical, but the underlying biology is real.

A 2023 commentary in the Journal of Drugs in Dermatology (Atkinson and Bhatt, 2023) noted increasing patient inquiries about facial volume loss following GLP-1 therapy, describing it as consistent with general lipodystrophy patterns seen in rapid weight reduction from other causes. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide users losing an average of 14.9% of body weight over 68 weeks. That kind of loss does not spare the face. Skin laxity follows fat loss because dermal collagen and elastin cannot remodel quickly enough to compensate, a process influenced by age, genetics, and rate of weight loss (Krueger and Bhatt, 2022, Dermatologic Surgery).

• GLP-1-associated facial volume loss is real and documented anecdotally in dermatology literature.
• Rapid weight loss increases loose skin risk regardless of the method used to achieve it.
• Slower weight loss does not fully prevent skin laxity, but it may reduce severity.

What did they get wrong or right?

We cannot assign right or wrong to a transcript that reads as audio noise. That is a genuine limitation here, not a dodge. The creator's credentials as a dermatologist, if accurate, suggest the intended content may well have been clinically sound. Dermatologists in the Gulf region are increasingly addressing GLP-1 aesthetic side effects as semaglutide prescribing has expanded significantly across Saudi Arabia, the UAE, and Egypt.

What we can say plainly: any claim that a specific skin treatment reverses GLP-1-related skin laxity should be viewed skeptically. Radiofrequency, ultrasound, and filler-based interventions have limited peer-reviewed evidence specifically in post-GLP-1 patients. The field is genuinely moving faster than the research. A dermatologist who acknowledges that gap is being honest. One who promises a fix is overselling.

What should you actually know about loose skin and GLP-1 drugs?

Loose skin after significant GLP-1-driven weight loss is common, not universal, and not fully preventable. Several factors raise your risk: age over 40, weight loss exceeding 20% of body weight, pre-existing low skin elasticity, and a rapid loss trajectory. Resistance training during weight loss has some evidence for preserving lean mass, which can partially offset skin laxity visually, though it does not change the dermis directly (Cava et al., 2017, Advances in Nutrition).

For patients considering cosmetic interventions post-weight-loss, the American Society of Plastic Surgeons recommends weight stabilization for at least three to six months before surgical procedures. That guidance applies equally to patients who lost weight on semaglutide or tirzepatide. Jumping into body contouring procedures while still actively losing weight on a GLP-1 medication is poor timing and some surgeons are now explicitly factoring ongoing GLP-1 use into pre-operative assessments.

• Protein intake adequacy during GLP-1 therapy matters for skin and muscle preservation.
• No topical product has strong clinical evidence for reversing post-weight-loss skin laxity.
• Surgical options exist but require weight stability first.